A common mistake is treating device security as a launch problem instead of a lifecycle obligation. The regulation expects controls from design through decommissioning, including threat modelling, vulnerability assessment, patching, and secure disposal. Teams also miss the need to define how devices can be misused at each stage and to assign responsibilities across security, development, and legal.
Why lifecycle security is the real obligation, not a launch checklist
For medical device manufacturers, the core mistake is narrowing cybersecurity to premarket design and validation. A device can be secure at release and still become unsafe later if vulnerabilities emerge, software dependencies change, credentials age, or support ends. Lifecycle obligations are about maintaining a defensible security posture while the device remains in use, serviced, updated, or retired.
That means cybersecurity work must track the device’s real operating life, not just its approval milestone. The security case should anticipate how the product will be updated, how threats may change, what telemetry or logging is available, and how the manufacturer will continue to assess and respond to newly discovered weaknesses after deployment.
Manufacturers also need a clear view of how lifecycle obligations connect to secure by design expectations. The point is not only to build a safer device, but to prove that security decisions survive long-term operation, field support, and eventual decommissioning.
What manufacturers often miss at each stage of the device lifecycle
Many teams design for the initial threat model, then fail to keep that model current. A device may accumulate new exposure through third-party components, connected services, remote maintenance paths, or changed clinical workflows. If the threat model is never revisited, the manufacturer stops seeing realistic misuse paths, and the control set starts drifting away from the actual deployment environment.
Vulnerability handling is another common gap. Lifecycle obligation means more than saying a device is secure at shipment. It requires a process for intake, assessment, prioritisation, patching, customer communication, and when necessary, compensating controls if remediation cannot happen immediately. That is where guidance such as the CISA Known Exploited Vulnerabilities Catalog is useful as a reminder that exploited weaknesses require active management, not passive documentation.
Decommissioning is often treated as an operations detail, but it is part of the security lifecycle. Secure disposal, credential retirement, configuration removal, and data handling all matter because a retired device can still expose secrets, network access, or residual trust relationships if it is not formally closed out.
Why responsibility and misuse analysis fail when they are left informal
Lifecycle obligations are also organisational, not just technical. Manufacturers frequently underdefine who owns post-release security, who approves risk acceptance, and who coordinates across engineering, product, security, legal, and field support. When ownership is fuzzy, patch decisions stall, disclosure responses become inconsistent, and support commitments may not match the actual product risk.
Teams also under-specify misuse. The regulation expects manufacturers to think through how the device can be abused at each stage, not only how it is intended to work. That includes unsafe access paths, privilege misuse, unintended persistence, and ways clinical or service workflows can be turned into an attack path. A lifecycle plan is stronger when it explains the trust boundaries and failure modes a real operator or adversary could exploit.
For readers who want a practical ownership model, Joiner-Mover-Leaver (JML) Guide is a useful analogue for thinking about lifecycle transitions: who gets access, who loses it, and what must be revoked or reassigned when the context changes. In device security, the same logic applies to support accounts, service channels, and retired assets.
Risk and Threat Considerations
The risk is not just that a device has a bug, it is that the bug survives into real clinical use because lifecycle controls were never built to catch it. That creates exposure through long-lived vulnerabilities, unrevoked support access, stale assumptions about network exposure, and devices that remain deployed after their security support window has effectively ended.
Failure mechanism: Security teams treat release approval as the finish line, so threat models, patch workflows, and disposal controls are not maintained after deployment. Over time, that leaves exploitable weaknesses, unresolved misuse paths, and unsupported devices in the field.
Impact: The manufacturer can lose control over the product’s security posture, while healthcare operators inherit avoidable exposure to compromise, service disruption, unsafe access, and remediation costs that are much harder to contain once the device is widespread.
Standards & Framework Alignment
This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.
NIST CSF 2.0 and NIST SP 800-53 Rev 5 set the technical controls, while ISO/IEC 27001:2022 and EU Cyber Resilience Act define the regulatory obligations.
| Framework | Control / Reference | Relevance |
|---|---|---|
| NIST CSF 2.0 | GV.SC-01 — Supply Chain Risk Management | Lifecycle device security depends on managing third-party and long-term exposure. |
| Recommendation — Track supplier and update risk across the device lifecycle. | ||
| NIST SP 800-53 Rev 5 | SI-2 — Flaw Remediation | The answer centers on ongoing vulnerability assessment and patching after release. |
| Recommendation — Maintain continuous flaw remediation for deployed devices. | ||
| ISO/IEC 27001:2022 | A.8.8 — Management of technical vulnerabilities | Manufacturers must handle vulnerabilities throughout support and operation, not only at launch. |
| Recommendation — Run a vulnerability management process that covers the full product lifecycle. | ||
| EU Cyber Resilience Act | Cyber Resilience Act | The question concerns lifecycle cybersecurity duties for products with digital elements. |
| Recommendation — Design and maintain products for secure lifecycle support and update handling. | ||
Practitioner Guidance
What to prioritise: Establish one lifecycle owner for every device family and make that owner responsible for threat-model refresh, vulnerability intake, patch coordination, and retirement criteria. If no team can name the current control owner for post-release security, the lifecycle obligation is already failing.
What to verify: Confirm that the product has a documented path for vulnerability disclosure, patch validation, customer notification, and end-of-support handling. The strongest evidence is not a security statement in the dossier, but an operational process that can actually be executed when a field issue appears.
Practitioner takeaway: Medical device cybersecurity is not mainly about proving the product was safe at launch, it is about proving the manufacturer can keep it supportably secure until the device is retired.
Related resources from NHI Mgmt Group
- What do organisations get wrong about patching medical device vulnerabilities?
- What do security teams get wrong about medical device security documentation?
- What do organisations get wrong about UAE data privacy and cybersecurity obligations?
- What do security teams get wrong about passkeys and device loss?
Deepen Your Knowledge
Reviewed and updated by the NHIMG editorial team on September 29, 2026.
NHI Mgmt Group — the #1 independent authority on Non-Human Identity, IAM, and Agentic AI security. nhimg.org
